A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer
- Author
- CRISTOFANILLI, Massimo1 ; JOHNSTON, Stephen R. D2 ; RANGANATHAN, Sulabha9 ; REDHU, Suman9 ; TRUDEAU, Maureen E10 ; MANIKHAS, Alexey3 ; GOMEZ, Henry L4 ; GLADKOV, Oleg5 ; ZHIMIN SHAO6 ; SAFINA, Sufia7 ; BLACKWELL, Kimberly L8 ; ALVAREZ, Ricardo H1 ; RUBIN, Stephen D9
[1] MD Anderson Cancer Center, Houston, TX, United States
[2] The Royal Marsden NHS Foundation Trust, London, United Kingdom
[3] St. Petersburg City Oncological Dispensary, St. Petersburg, Russian Federation
[4] Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru
[5] Regional Oncology Dispensary, Chelyabinsk, Russian Federation
[6] Cancer Hospital of Shanghai Fudan University, Shanghai, China
[7] City Oncology Dispensary, Kazan, Russian Federation
[8] Duke Cancer Institute, Durham, NC, United States
[9] GlaxoSmithKline, Collegeville, PA, United States
[10] Sunnybrook Odette Cancer Centre, Toronto, ON, Canada - Source
Breast cancer research and treatment. 2013, Vol 137, Num 2, pp 471-482, 12 p ; ref : 30 ref
- CODEN
- BCTRD6
- ISSN
- 0167-6806
- Scientific domain
- Medical oncology; Obstetrics, gynecology, andrology; Pharmacology drugs
- Publisher
- Springer, Dordrecht
- Publication country
- Netherlands
- Document type
- Article
- Language
- Russian
- Author keyword
- HER2-positive breast cancer Inflammatory breast cancer Lapatinib Pazopanib
- Keyword (fr)
- Anticancéreux Cancer du sein Essai clinique phase II Etude comparative Gène erbB2 Gène onc cellulaire Homme Inflammation Lapatinib Malade Pazopanib Protooncogène Randomisation Toxicité Traitement Anti-VEGF Récepteur HER2 Cancer Enzyme Inhibiteur de la tyrosine kinase Inhibiteur enzyme Pathologie de la glande mammaire Pathologie du sein Protein-tyrosine kinase Transferases Tumeur maligne
- Keyword (en)
- Antineoplastic agent Breast cancer Phase II trial Comparative study erbB2 Gene C-Onc gene Human Inflammation Lapatinib Patient Pazopanib Protooncogene Randomization Toxicity Treatment Human Epidermal growth factor Receptor 2 Cancer Enzyme Tyrosine kinase inhibitor Enzyme inhibitor Mammary gland diseases Breast disease Protein-tyrosine kinase Transferases Malignant tumor
- Keyword (es)
- Anticanceroso Cáncer del pecho Ensayo clínico fase II Estudio comparativo Gen erbB2 Gen onc celular Hombre Inflamación Lapatinib Enfermo Pazopanib Protooncogen Aleatorización Toxicidad Tratamiento Cáncer Enzima Inhibidor tyrosine kinase Inhibidor enzima Glándula mamaria patología Seno patología Protein-tyrosine kinase Transferases Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B04 Tumors / 002B04C Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B20 Gynecology. Andrology. Obstetrics / 002B20E Mammary gland diseases / 002B20E02 Tumors
- Discipline
- Gynecology. Andrology. Obstetrics Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 27579254
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1007/s10549-012-2369-x 
https://dx.doi.org/10.1007/s10549-012-2369-x
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s10549-012-2369-x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:119:\"A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Breast cancer research and treatment\";s:9:\"\u0000*\u0000stitle\";s:24:\"Breast cancer res. treat\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"137\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"471\";s:8:\"\u0000*\u0000epage\";s:3:\"482\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0167-6806\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:13:\"CRISTOFANILLI\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Massimo\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:22:\"JOHNSTON, Stephen R. D\";i:1;s:20:\"RANGANATHAN, Sulabha\";i:2;s:12:\"REDHU, Suman\";i:3;s:18:\"TRUDEAU, Maureen E\";i:4;s:16:\"MANIKHAS, Alexey\";i:5;s:14:\"GOMEZ, Henry L\";i:6;s:13:\"GLADKOV, Oleg\";i:7;s:11:\"ZHIMIN SHAO\";i:8;s:13:\"SAFINA, Sufia\";i:9;s:21:\"BLACKWELL, Kimberly L\";i:10;s:18:\"ALVAREZ, Ricardo H\";i:11;s:16:\"RUBIN, Stephen D\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BCTRD6\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:119:\"A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer\";s:8:\"\u0000*\u0000place\";s:9:\"Dordrecht\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s10549-012-2369-x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:119:\"A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Breast cancer research and treatment\";s:9:\"\u0000*\u0000stitle\";s:24:\"Breast cancer res. treat\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"137\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"471\";s:8:\"\u0000*\u0000epage\";s:3:\"482\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0167-6806\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:13:\"CRISTOFANILLI\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Massimo\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:22:\"JOHNSTON, Stephen R. D\";i:1;s:20:\"RANGANATHAN, Sulabha\";i:2;s:12:\"REDHU, Suman\";i:3;s:18:\"TRUDEAU, Maureen E\";i:4;s:16:\"MANIKHAS, Alexey\";i:5;s:14:\"GOMEZ, Henry L\";i:6;s:13:\"GLADKOV, Oleg\";i:7;s:11:\"ZHIMIN SHAO\";i:8;s:13:\"SAFINA, Sufia\";i:9;s:21:\"BLACKWELL, Kimberly L\";i:10;s:18:\"ALVAREZ, Ricardo H\";i:11;s:16:\"RUBIN, Stephen D\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BCTRD6\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:119:\"A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer\";s:8:\"\u0000*\u0000place\";s:9:\"Dordrecht\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s10549-012-2369-x\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s10549-012-2369-x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:119:\"A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Breast cancer research and treatment\";s:9:\"\u0000*\u0000stitle\";s:24:\"Breast cancer res. treat\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"137\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"471\";s:8:\"\u0000*\u0000epage\";s:3:\"482\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0167-6806\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:13:\"CRISTOFANILLI\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Massimo\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:22:\"JOHNSTON, Stephen R. D\";i:1;s:20:\"RANGANATHAN, Sulabha\";i:2;s:12:\"REDHU, Suman\";i:3;s:18:\"TRUDEAU, Maureen E\";i:4;s:16:\"MANIKHAS, Alexey\";i:5;s:14:\"GOMEZ, Henry L\";i:6;s:13:\"GLADKOV, Oleg\";i:7;s:11:\"ZHIMIN SHAO\";i:8;s:13:\"SAFINA, Sufia\";i:9;s:21:\"BLACKWELL, Kimberly L\";i:10;s:18:\"ALVAREZ, Ricardo H\";i:11;s:16:\"RUBIN, Stephen D\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BCTRD6\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:119:\"A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer\";s:8:\"\u0000*\u0000place\";s:9:\"Dordrecht\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s10549-012-2369-x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:119:\"A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Breast cancer research and treatment\";s:9:\"\u0000*\u0000stitle\";s:24:\"Breast cancer res. treat\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"137\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"471\";s:8:\"\u0000*\u0000epage\";s:3:\"482\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0167-6806\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:13:\"CRISTOFANILLI\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Massimo\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:22:\"JOHNSTON, Stephen R. D\";i:1;s:20:\"RANGANATHAN, Sulabha\";i:2;s:12:\"REDHU, Suman\";i:3;s:18:\"TRUDEAU, Maureen E\";i:4;s:16:\"MANIKHAS, Alexey\";i:5;s:14:\"GOMEZ, Henry L\";i:6;s:13:\"GLADKOV, Oleg\";i:7;s:11:\"ZHIMIN SHAO\";i:8;s:13:\"SAFINA, Sufia\";i:9;s:21:\"BLACKWELL, Kimberly L\";i:10;s:18:\"ALVAREZ, Ricardo H\";i:11;s:16:\"RUBIN, Stephen D\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BCTRD6\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:119:\"A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer\";s:8:\"\u0000*\u0000place\";s:9:\"Dordrecht\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s10549-012-2369-x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:119:\"A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Breast cancer research and treatment\";s:9:\"\u0000*\u0000stitle\";s:24:\"Breast cancer res. treat\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"137\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"471\";s:8:\"\u0000*\u0000epage\";s:3:\"482\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0167-6806\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:13:\"CRISTOFANILLI\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Massimo\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:22:\"JOHNSTON, Stephen R. D\";i:1;s:20:\"RANGANATHAN, Sulabha\";i:2;s:12:\"REDHU, Suman\";i:3;s:18:\"TRUDEAU, Maureen E\";i:4;s:16:\"MANIKHAS, Alexey\";i:5;s:14:\"GOMEZ, Henry L\";i:6;s:13:\"GLADKOV, Oleg\";i:7;s:11:\"ZHIMIN SHAO\";i:8;s:13:\"SAFINA, Sufia\";i:9;s:21:\"BLACKWELL, Kimberly L\";i:10;s:18:\"ALVAREZ, Ricardo H\";i:11;s:16:\"RUBIN, Stephen D\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BCTRD6\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:119:\"A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer\";s:8:\"\u0000*\u0000place\";s:9:\"Dordrecht\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
